Full Description
Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments.
These therapies notably include:
Targeted agents of immune checkpoints
Signal-transduction inhibitors
Antiangiogenic agents
Vascular-disrupting agents
Apoptosis modulators
Stem cell inhibitors
Tumor profiling for drug development
The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.
Contents
Role of Next-Generation Sequencing Technologies. Signal Transduction Inhibitors of the HER Family. HER2 Inhibition and Clinical Achievements. Inhibiting the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway.
BRAF and MEK Inhibitors. KIT and KIT Inhibitors. Targeting the Fibroblast Growth Factor Receptor Pathway in Human Cancer. Anaplastic Lymphoma Kinase. MET Inhibitors. Targeting Stem Cells. The Cancer Super-Chaperone Hsp90: Its Posttranslational Regulation and Drug Targeting. Targeting Apoptosis Pathways. Targeting Angiogenesis. Antivascular Agents. Immunotherapy: Monoclonal Antibodies (CTLA4, PD-1, PD-L1, IL-18, and IL-21).
Vaccine Therapy and Integration with Other Modalities. Histone Deacetylase Inhibitors as Targeted Therapies.
Compounds Targeting Androgen Pathways. Targeting DNA Repair: PARP and Chk1 Inhibitors. Inhibitors Targeting Mitosis. Index.
